Kommisjonens gjennomføringsbeslutning (EU) 2026/1420 av 30. juni 2026 om avslag på godkjenning av terbutryn, 1,2-Benzisotiazol-3(2H)-one (BIT) og tetrahydro1,3,4,6-tetrakis(hydroxymethyl)imidazo[4,5-d]imidazole-2,5(1H,3H)-dione (TMAD) som eksisterende aktive stoffer til bruk i biocidprodukter av type 9, 9 og 12, henholdsvis, i samsvar med europaparlaments- og rådsforordning (EU) nr. 528/2012
Biocider: avslag på godkjenning av visse eksisterende stoffer til bruk i produkttype 9 og 12
Commission Implementing Decision (EU) 2026/1420 of 30 June 2026 on the non-approval of terbutryn, 1,2-Benzisothiazol-3(2H)-one (BIT) and tetrahydro-1,3,4,6-tetrakis(hydroxymethyl)imidazo[4,5-d]imidazole-2,5(1H,3H)-dione (TMAD) as existing active substances for use in biocidal products of product-types 9, 9, and 12, respectively, in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council
Kommisjonsbeslutning publisert i EU-tidende 3.7.2026
Tidligere
- Utkast til kommisjonsbeslutning godkjent av komite (representanter for medlemslandene) og publisert i EUs komitologiregister 16.6.2026
Bakgrunn
(fra kommisjonsbeslutningen)
(1) Commission Delegated Regulation (EU) No 1062/2014 establishes in its Annex II a list of active substance/product-type combinations included in the review programme of existing active substances in biocidal products.
(2) For a number of active substance/product-type combinations included in that list, all the participants have withdrawn or are considered to have withdrawn their support in a timely manner.
(3) In accordance with Article 14(1) of Delegated Regulation (EU) No 1062/2014, the European Chemicals Agency (‘the Agency’) published an open invitation to take over the role of participant for those active substance/product-type combinations for which the role of a participant had not previously been taken over. For those combinations no notification has been submitted to the Agency within the time limit provided for by Article 14(2) of Delegated Regulation (EU) No 1062/2014. Therefore, those active substance/product-type combinations, in accordance with Article 20, first paragraph, point (b), of that Delegated Regulation, should not be approved for use in biocidal products. Those active substance/product-type combinations are the following:
(a) terbutryn (product-type 9);
(b) 1,2-Benzisothiazol-3(2H)-one (BIT) (product-type 9);
(c) tetrahydro-1,3,4,6-tetrakis(hydroxymethyl)imidazo[4,5-d]imidazole2,5(1H,3H)-dione (TMAD) (product-type 12).
(4) The measures provided for in this Decision are in accordance with the opinion of the Standing Committee on Biocidal Products,